Gilead pays Nimbus $200M after fast progress in NASH


Nimbus Therapeutics first made its name hustling a NASH drug from initial screening to the cusp of Phase I in 16 months. Now, it is proving equally adept at pulling in money at an eye-catching rate. Six months after Gilead ($GILD) paid Nimbus $400 million to buy the NASH drug, it has handed over another $200 million milestone payment.

The milestone payout means Nimbus has pocketed half of the potential $1.2 billion value of the deal within six months of it closing.

R&D progress has been similarly rapid. Since closing the deal in May, Gilead has initiated four clinical trials of the allosteric acetyl-CoA carboxylase (ACC) inhibitor. A trial to assess the pharmacodynamics of the ACC inhibitor, now known as GS-0976, in obese but otherwise healthy men has already come and gone. And Gilead is in the middle of another Phase I study to assess the pharmacokinetics of GS-0976 in adults with normal and impaired hepatic function.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The rest of the R&D program consists of a pair of Phase II trials.

One of the studies is comparing GS-0976 to placebo in a forecast 125 patients with NASH. The trial is primarily looking at the safety of GS-0976, but Gilead is also hoping to glean some insights into efficacy.

The other trial started out as an open-label assessment of Gilead’s apoptosis signal-regulating kinase 1 inhibitor GS-4997, but was expanded following the Nimbus deal to include GS-0976 and farnesoid X-activated receptor agonist GS-9674. Gilead acquired GS-9674 in the 2015 acquisition of Phenex Pharmaceuticals’ NASH program. Three cohorts of patients with non-alcoholic fatty liver disease (NAFLD) will each receive one of the drugs for 12 weeks. NASH in a severe form of NAFLD.

That 30-person study is indicative of the multi-front NASH drive now underway at Gilead. The Big Biotech delivered data from a mid-stage trial of GS-4997 in NASH last month, setting it up to move into Phase III study once it has wrapped up talks with regulators. While pushing forward with GS-4997, Gilead has pulled the plug on another of its NASH hopefuls, simtuzumab.

Gilead’s fast rollout of a clutch of trials featuring the drug it bought from Nimbus is keeping with the program’s development to date. The ACC inhibitor acted as a proving ground for the computational chemistry-enabled approach to drug design Nimbus created with Schrödinger. That method enabled the rapid advance of the NASH drug toward the clinic.

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.